Facing Today’s Challenges in Pancreatic Cancer Treatment - Webinar of 6/21/22

0 Views

07/13/23

(NASDAQ: RNXT) Join Dr. Michael Pishvaian, Study Chair for the Phase 3 TIGeR-PaC clinical trial, and RenovoRx's CEO, Shaun Bagai as they address currently available treatment options for pancreatic cancer and why they can fall short of providing an effective solution in fighting this deadly disease, and how the RenovoRx therapy platform re-envisions the treatment of pancreatic and other solid tumors with the goal of improving survival and quality of life for patients undergoing chemotherapy. Additionally, the presentation covers the Company’s plan for expanding the utility of its innovative therapy platform and its anticipated milestones for the remainder of the year.
-------------------------------------------
RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult-to-treat tumors via its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and our patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase 3 TIGeR-PaC trial for the treatment of LAPC.

To learn visit and follow us at:

Website: https://www.RenovoRx.com
Facebook: https://www.facebook.com/RenovoRx
Twitter: https://twitter.com/RenovoRx
LinkedIn: https://www.linkedin.com/company/RenovoRx